An exploration of irisin to improve the prognosis of ARDS by inhibiting ferroptosis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043941

Enrollment

Unknown

Registered

2021-03-06

Start date

2021-03-05

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory distress syndrome

Interventions

Case group :No

healthy control group:No

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ICU patients with acute respiratory distress syndrome induced by intrapulmonary or extrapulmonary factors (see Berlin definition criteria for details); 2. The control group was healthy volunteers.

Exclusion criteria

Exclusion criteria: 1. Aged < 18 years; 2. Receiving immunosuppressant or long-term glucocorticoid therapy (0.5mg/Kg/d, 1 month); 3. a history of diagnosed or suspected malignant tumor; 4. Other experiments have been included.

Design outcomes

Primary

Measure	Time frame
glutathione;Malondialdehyde;TfR1;irisin;	—

Countries

China

Contacts

Public ContactDaoxin Wang

The Second Affiliated Hospital of Chongqing Medical University

lxzxwhh@163.com+86 13983680899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026